Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

Simply Wall St.08-05 23:29

In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indications for BOTOX Cosmetic and RINVOQ, and saw...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657529584?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","is_english":true,"pubTime":"2026-08-05 23:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657529584","market":"us","top_or_hot":-1,"title":"Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?","media":"Simply Wall St.","content":"<div>\n<p>In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indications for BOTOX Cosmetic and RINVOQ, and saw...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvies-abbv-botox-masseter-bet-quietly-rewriting-its-pos\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-05 23:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvies-abbv-botox-masseter-bet-quietly-rewriting-its-pos><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indications for BOTOX Cosmetic and RINVOQ, and saw...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvies-abbv-botox-masseter-bet-quietly-rewriting-its-pos\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1551013425.SGD","symbol_name":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvies-abbv-botox-masseter-bet-quietly-rewriting-its-pos","article_id":"2657529584","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvies-abbv-botox-masseter-bet-quietly-rewriting-its-pos","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2657529584","pubTimestamp":1785943798,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indications for BOTOX Cosmetic and RINVOQ, and saw a Canadian reimbursement recommendation for UBRELVY. \nTogether with multiple new bond issues totaling roughly US$6.00 billion, these updates underline AbbVie’s push to broaden its portfolio while actively managing its capital structure.\nWe’ll now examine how the new BOTOX Cosmetic masseter...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","PPH":"VanEck Pharmaceutical ETF","VHT":"Vanguard Health Care ETF","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","POST":"Post Holdings","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IYH":"iShares U.S. Healthcare ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4581":"高盛持仓","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","PJP":"INVESCO PHARMACEUTICALS ETF","AGNG":"Global X Aging Population ETF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","TRUH":"VanEck Healthcare TruSector ETF","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE000MB6IJN5.SGD":"RQI GLOBAL \"I\" (SGD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","ABBV":"艾伯维公司","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","RXL":"ProShares Ultra Health Care","MEDX":"HORIZON KINETICS MEDICAL ETF","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","FHLC":"Fidelity MSCI Health Care Index","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","IXJ":"全球医疗业ETF-iShares"},"translate_title":"艾伯维 (ABBV) 的肉毒杆菌咬合器 Bet 是否正在悄然改写其后修美乐时代的增长故事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXJ":0.6,"VHT":0.6,"XLV":0.6,"RXL":0.6,"JDOC":0.6,"MEDX":0.6,"ABBV":1.5,"PPH":0.6,"PJP":0.6,"POST":1.5,"FTXH":0.6,"FHLC":0.6,"AGNG":0.6,"GLAM":0.6,"IYH":0.6,"TRUH":0.6},"content_text":"In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indications for BOTOX Cosmetic and RINVOQ, and saw a Canadian reimbursement recommendation for UBRELVY.  Together with multiple new bond issues totaling roughly US$6.00 billion, these updates underline AbbVie’s push to broaden its portfolio while actively managing its capital structure. We’ll now examine how the new BOTOX Cosmetic masseter indication filing could reshape AbbVie’s investment narrative and long-term growth mix. Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementAbbVie Investment Narrative RecapTo own AbbVie, you need to be comfortable with a large-cap pharma that leans heavily on immunology and neuroscience, while using aesthetics and oncology to round out growth. The latest quarter’s stronger results and higher 2026 revenue outlook support that thesis, but the key near term catalyst remains continued uptake and indication expansion for Skyrizi and Rinvoq, while concentrated product risk and pricing pressure still sit at the center of the downside case. The new updates do not materially change those priorities. Among the recent announcements, the FDA’s acceptance of the BOTOX Cosmetic masseter indication filing stands out as most relevant here, because it speaks directly to AbbVie’s effort to deepen its aesthetics franchise beyond traditional wrinkle treatments. If approved, it would add a differentiated, procedure based use case at a time when investors are watching whether aesthetics can provide a steadier, more diversified earnings mix alongside immunology and neuroscience. Yet while these developments are encouraging, investors should also be aware that concentrated exposure to a handful of core products could... Read the full narrative on AbbVie (it's free!)AbbVie’s narrative projects $79.2 billion revenue and $23.1 billion earnings by 2029. This requires 8.0% yearly revenue growth and about a $19.5 billion earnings increase from $3.6 billion today.Uncover how AbbVie's forecasts yield a $266.89 fair value, a 9% upside to its current price.Exploring Other PerspectivesABBV 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community span roughly US$266.89 to US$398.52 per share, showing how far apart individual views can be. Set against AbbVie’s reliance on a concentrated product portfolio, this spread underlines why it can be useful to compare several independent perspectives before forming a view on the company’s prospects.Explore 3 other fair value estimates on AbbVie - why the stock might be worth just $266.89!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your AbbVie research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.Interested In Other Possibilities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with 20 elite penny stocks that balance risk and reward.The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657529584","isCrawlerRequest":true}